Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Recent health news highlights Britain's decision not to support the bioethanol industry, Berkshire Hathaway's investment in ...

The UK's bioethanol industry faces collapse due to the trade deal with Trump, leaving the government opting not to intervene.

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno Therapeutics's announcement, with hopes high for news of surpassing ...

REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

--Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced updates to its Board of Directors.

REDWOOD CITY, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...